Examkin

Soru

Zorluk: ZorSubstance-Related and Addictive Disorders

A 32-year-old woman presents to an outpatient addiction medicine clinic seeking treatment for severe opioid use disorder. She reports using intravenous heroin daily for the past 3 years and expresses a strong desire to stop. She is currently not intoxicated and shows no signs of opioid withdrawal, having last used heroin 2 hours ago. She and the physician agree to initiate buprenorphine/naloxone therapy. Arrange the following clinical steps in the correct chronological sequence required to safely and effectively initiate and maintain this pharmacotherapy.

  1. 1Instruct the patient to abstain from short-acting opioids for at least 12 to 24 hours.
  2. 2Verify the onset of mild-to-moderate withdrawal symptoms using the Clinical Opiate Withdrawal Scale (COWS).
  3. 3Administer the initial induction dose of sublingual buprenorphine/naloxone.
  4. 4Titrate the buprenorphine dosage over several days to adequately suppress illicit opioid cravings.
  5. 5Transition the patient to long-term maintenance pharmacotherapy integrated with cognitive behavioral therapy.

Cevap

The correct sequence is to first instruct the patient to abstain from opioids, verify the onset of withdrawal symptoms, administer the initial induction dose, titrate the dosage over several days, and finally transition to long-term maintenance therapy.
Buprenorphine is a partial mu-opioid agonist with a very high receptor affinity but lower intrinsic activity compared to full agonists like heroin or methadone. If buprenorphine is administered while a full agonist is still occupying the receptors, it will competitively displace the full agonist, leading to a sudden, severe drop in overall opioid receptor activation. This causes precipitated opioid withdrawal, which is highly distressing and can cause treatment dropout. Therefore, the essential first step is for the patient to abstain from short-acting opioids for 12 to 24 hours. The physician must then objectively confirm that the patient is in mild-to-moderate withdrawal (typically using the Clinical Opiate Withdrawal Scale, or COWS, requiring a score of 8 or higher) before administering the initial induction dose. Once inducted safely, the dose is titrated over several days to effectively suppress cravings and block the effects of any illicit opioids. Finally, the patient is transitioned to a stable, long-term maintenance dose paired with psychosocial support.

Adım Adım Çözüm

1
Analyze the pharmacological properties of the chosen medication (buprenorphine).
Identify buprenorphine as a partial mu-opioid agonist with high binding affinity.
Understanding its high affinity explains its ability to displace full agonists, which dictates the strict timing required for induction.
2
Determine the necessary physiological state of the patient prior to first administration.
The patient must be in a state of mild-to-moderate opioid withdrawal.
If administered while full agonists (like heroin) still occupy receptors, buprenorphine will precipitate severe withdrawal. Abstinence followed by objective evaluation is mandatory.
3
Sequence the remaining clinical management steps after successful induction.
Initial administration is followed by daily dose titration, which then leads to long-term maintenance.
The dose must be optimized to suppress cravings before the patient can be safely transitioned to stable, long-term outpatient maintenance.

Anahtar Kavram

Buprenorphine induction requires the patient to be in mild-to-moderate opioid withdrawal to avoid precipitated withdrawal, due to its properties as a partial agonist with high receptor affinity.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Substance-Related and Addictive Disorders

Bu konudan daha fazla soru